VelosBio

← Back to Chiesi Portfolio

VelosBio Inc. is a near-term clinical-stage biopharmaceutical company focused on novel cancer targets.

VelosBio

San Diego, CA

11.05.2020

VelosBio to be Acquired by Merck for $2.75 billion

10.22.2020

VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-10…

logo_white

veteran_logo_white

NVCA

bio

nc-biotech

© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.

© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.